Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales).
Cancel M, Fromont G, Blonz C, Chevreau C, Rioux-Leclercq N, Laguerre B, Oudard S, Gross-Goupil M, Gravis G, Goldwasser F, Rolland F, Delva R, Moise L, Emambux S, Vassal C, Zanetta S, Penel N, Fléchon A, Barthélémy P, Saldana C, Lefort F, Escudier B, Linassier C, Albiges L. Cancel M, et al. Among authors: saldana c. Eur J Cancer. 2021 Oct 4;158:1-11. doi: 10.1016/j.ejca.2021.08.046. Online ahead of print. Eur J Cancer. 2021. PMID: 34619467
Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial Cells and in Human Nasal Epithelial Cells.
Majidipur A, Morin-Dewaele M, Gaspar Lopes J, Berry F, Fouchet J, Bartier S, Dufros Duval A, Soyeux P, Huet E, Louis B, Coste A, Béquignon É, Saldana C, Le Corvoisier P, Destouches D, Pawlotsky JM, de la Taille A, Vacherot F, Bruscella P, Firlej V. Majidipur A, et al. Among authors: saldana c. Int J Mol Sci. 2023 Feb 7;24(4):3288. doi: 10.3390/ijms24043288. Int J Mol Sci. 2023. PMID: 36834705 Free PMC article.
First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
Rousseau B, Kempf E, Desamericq G, Boissier E, Chaubet-Houdu M, Joly C, Saldana C, Boussion H, Neuzillet C, Macquin-Mavier I, Oudard S, Salomon L, de la Taille A, Tournigand C. Rousseau B, et al. Among authors: saldana c. Crit Rev Oncol Hematol. 2016 Nov;107:44-53. doi: 10.1016/j.critrevonc.2016.08.012. Epub 2016 Sep 1. Crit Rev Oncol Hematol. 2016. PMID: 27823651
Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
Muller M, Ferlicot S, Guillaud-Bataille M, Le Teuff G, Genestie C, Deveaux S, Slama A, Poulalhon N, Escudier B, Albiges L, Soufir N, Avril MF, Gardie B, Saldana C, Allory Y, Gimenez-Roqueplo AP, Bressac-de Paillerets B, Richard S, Benusiglio PR. Muller M, et al. Among authors: saldana c. Clin Genet. 2017 Dec;92(6):606-615. doi: 10.1111/cge.13014. Epub 2017 May 2. Clin Genet. 2017. PMID: 28300276
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
Colomba E, Le Teuff G, Eisen T, Stewart GD, Fife K, Larkin J, Biondo A, Pickering L, Srinivasan A, Boyle H, Derosa L, Sternberg CN, Recine F, Ralph C, Saldana C, Barthélémy P, Bernhard JC, Gurney H, Verhoest G, Vauleon E, Bigot P, Berger J, Pfister C, Gravis G, Rodier JM, Culine S, Caty A, Rolland F, Priou F, Escudier B, Albiges L. Colomba E, et al. Among authors: saldana c. Eur J Cancer. 2017 Jul;80:55-62. doi: 10.1016/j.ejca.2017.03.011. Epub 2017 May 23. Eur J Cancer. 2017. PMID: 28549248 Free article.
Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial.
Pfister C, Harter V, Allory Y, Radvanyi F, Culine S; VESPER Trial Investigators. Pfister C, et al. Contemp Clin Trials Commun. 2020 Jan 30;17:100536. doi: 10.1016/j.conctc.2020.100536. eCollection 2020 Mar. Contemp Clin Trials Commun. 2020. PMID: 32083220 Free PMC article.
Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
de Vries-Brilland M, Gross-Goupil M, Seegers V, Boughalem E, Beuselinck B, Thibault C, Chevreau C, Ladoire S, Barthélémy P, Negrier S, Borchiellini D, Huillard O, Geoffrois L, Gravis G, Saldana C, Thiery-Vuillemin A, Escudier B, Ravaud A, Albiges L. de Vries-Brilland M, et al. Among authors: saldana c. Eur J Cancer. 2020 Sep;136:76-83. doi: 10.1016/j.ejca.2020.02.019. Epub 2020 Jul 9. Eur J Cancer. 2020. PMID: 32653774
Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma.
Carril-Ajuria L, Colomba E, Cerbone L, Romero-Ferreiro C, Crouzet L, Laguerre B, Thibault C, Vicier C, de Velasco G, Fléchon A, Saldana C, Benusiglio PR, Bressac-de Paillerets B, Guillaud-Bataille M, Gaignard P, Scoazec JY, Richard S, Caron O, Escudier B, Albiges L. Carril-Ajuria L, et al. Among authors: saldana c. Eur J Cancer. 2021 Jul;151:106-114. doi: 10.1016/j.ejca.2021.04.009. Epub 2021 May 8. Eur J Cancer. 2021. PMID: 33975058
Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data.
Barthélémy P, Rioux-Leclercq N, Thibault C, Saldana C, Borchiellini D, Chevreau C, Desmoulins I, Gobert A, Hilgers W, Khalil A, Lemoine N, Schlürmann-Constans F, Négrier S. Barthélémy P, et al. Among authors: saldana c. Cancer Treat Rev. 2021 Jun;97:102191. doi: 10.1016/j.ctrv.2021.102191. Epub 2021 Apr 9. Cancer Treat Rev. 2021. PMID: 34015728 Free article. Review.
134 results